scholarly journals Bone loss at subchondral plate in knee osteoarthritis patients with hypertension and type 2 diabetes mellitus

2013 ◽  
Vol 21 (11) ◽  
pp. 1716-1723 ◽  
Author(s):  
C.Y. Wen ◽  
Y. Chen ◽  
H.L. Tang ◽  
C.H. Yan ◽  
W.W. Lu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Loss ◽  
Knee Osteoarthritis ◽  
Subchondral Plate

Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

2010 ◽  
Vol 21 (12) ◽  
pp. 2013-2018 ◽  
Author(s):  
I. Kanazawa ◽  
T. Yamaguchi ◽  
S. Yano ◽  
M. Yamamoto ◽  
M. Yamauchi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Loss ◽  
Pioglitazone Treatment

scholarly journals Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats

2020 ◽  
Author(s):  
Ahmad Gholami ◽  
Mohammad Hossein Dabbaghmanesh ◽  
Younes Ghasemi ◽  
Pedram Talezadeh ◽  
Farhad Koohpeyma ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Loss ◽  
Lactobacillus Reuteri ◽  
Diabetic Rats ◽  
Urinary Calcium ◽  
Diabetic Patients ◽  
Protective Effects

Abstract Background Pioglitazone as a PPAR-g agonist are used for management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPARg activity using Pioglitazone may be linked with bone mass reduction and fracture risk in type 2 diabetes mellitus patients. The objective of the current research was to inspect the preventive role of some types of probiotic strains including ( Lactobacillus acidophilus , Lactobacillus reuteri , Lactobacillus casei , Bifidiobacterum longum and Bacillus coagulans ) against pioglitazone-induced bone loss. Methods Streptozotocin (60 mg/kg) was administered for diabetes induction. Diabetic rats were fed orally with pioglitazone (300 mg/kg) and probiotics (1×109 CFU/ml/day) alone and in combination of both for 4 weeks. Dual energy X-ray absorptiometry (DEXA) were used to asses BMD, BMC and area of the femur, spine and tibia at the experiment termination. Serum glucose, serum calcium, alkaline phosphatase, phosphorus, BUN, Creatinine, and urine calcium were also analyzed. Results Administration of pioglitazone and probiotics alone and in combination significantly improved elevated blood glucose. Pioglitazone treatment significantly increased urinary calcium and BUN, and decreased ALP and creatinine. Co-treatment of probiotics with pioglitazone significantly decreased urinary calcium, creatinine and ALP. Pioglitazone showed detrimental effects on femur-BMD whereas treatment with probiotics remarkably ameliorated these effects. Among the tested probiotics Bifidiobacterum longum displayed the best protective effects on pioglitazone-induced bone loss in diabetic rats. Conclusion This study suggests probiotic supplementation in diabetic patients on pioglitazone regime could be considering as a good strategy to ameliorate bone loss induced by pioglitazone.

scholarly journals Association of type 2 diabetes mellitus with self-reported knee pain and clinical knee osteoarthritis: The Maastricht Study

2018 ◽  
Vol 44 (3) ◽  
pp. 296-299 ◽  
Author(s):  
J.T.H. Nielen ◽  
P.J. Emans ◽  
B. van den Bemt ◽  
P.C. Dagnelie ◽  
M.T. Schram ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Knee Osteoarthritis ◽  
Knee Pain

scholarly journals Knee Osteoarthritis in Type 2 Diabetes Mellitus: Does Insulin Therapy Retard Osteophyte Formation?

2015 ◽  
Vol 25 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Khaled Al-Jarallah ◽  
Diaa Shehab ◽  
Nabila Abdella ◽  
Hisham Al Mohamedy ◽  
Mini Abraham
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Knee Osteoarthritis ◽  
Insulin Therapy ◽  
Osteophyte Formation

scholarly journals Clinical and Radiographic Variables Around Implant With Simultaneous Graft Among Type 2 Diabetic Patients Treated With Different Hypoglycemic Medications: A Retrospective Study.

2020 ◽  
Author(s):  
Shaojie Shi ◽  
Feng Ding ◽  
Xiangdong Liu ◽  
Lei Wang ◽  
Xingxing Wang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Bone Loss ◽  
Hypoglycemic Agents ◽  
Marginal Bone Loss ◽  
Insulin Group ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Abstract Background: The clinical and radiographic variables around dental implants in type 2 diabetes mellitus patients with different hypoglycemic agents still remained unclear.Methods: This retrospective cohort study collected the dental records and digital periapical radiographs of type 2 diabetes mellitus patients and implants. These patients were grouped according to their medication: insulin, metformin, and glucagon-like peptide-1 drugs. The radiographic marginal bone loss around implants and clinical parameters, including peri-implant bleeding on probing and probing depth, were compared among groups using the Kruskal-Wallis test.Results: A total of 150 patients with 308 implants (101 in insulin group, 121 in metformin group and 86 in glucagon-like peptide-1 drugs group) were assessed. The peri-implants marginal bone loss in insulin group (P<0.05) and metformin group (P<0.01) were significantly higher than glucagon-like peptide-1 drug group. The radiographic bone loss in metformin was higher than insulin group (P<0.05). While there was no statistical difference of clinical peri-implant parameters among groups(P>0.05).Conclusions: The radiographic variables were not exactly the same among type 2 diabetes mellitus patients with different hypoglycemic agents. glucagon-like peptide-1 drugs might be more beneficial to bone tissue around implants. More studies are needed to verify the direct effect of these drugs on peri-implant bone.Clinical trial registration number: ChiCTR2000034211 (retrospectively registered)

Sign in / Sign up

Export Citation Format

Share Document